Adaptive Biotechnologies, a sequencing and bioinformatics company based in Seattle, Washington, has appointed Diego Miralles as president of Adaptive Therapeutics. Miralles will build the Therapeutics Division of Adaptive, and head the company’s efforts to leverage its platform for identifying T- and B-cell receptors for use in therapies. He will provide both scientific and commercial guidance to the existing and future programs and partnerships that Adaptive is implementing
According to Xconomy, Adaptive Therapeutics will eventually be based in San Diego, while Miralles is initially spending his time in Seattle.
Miralles is a world leader in HIV therapeutics. He joined from Johnson & Johnson as Global Head of Innovation. Prior to this, he was Vice President at Tibotec. He worked as Assistant Professor at Duke University Health System from 1993 to 2005.
“Diego has an extensive scientific and pharmaceutical background and a strong reputation in leading and developing innovative drugs and businesses,” said Chad Robins, CEO of Adaptive Biotechnologies, adding that “we are looking forward to his experienced insight and strong leadership as he builds clinically impactful therapeutic programs for Adaptive.”
Last May, Adaptive completed its Series F financing round with a USD195 million investment to support several strategic growth initiatives. This round was led by Matrix Capital Management and included other new investors Senator Investment Group, Tiger Management, Rock Springs Capital and an additional large healthcare investor, alongside participation from existing investors Viking Global, Casdin Capital and Alexandria Real Estate Equities. Adaptive is also backed by industry-leading strategic investors Illumina, Celgene, BD Biosciences and LabCorp.